RUO · Not ApprovedGLP-1 / Glucagon✓ Free to read

Survodutide

A still-in-trials weight-loss shot that pairs the GLP-1 'full' signal with a glucagon 'burn more' signal, and is so new no reference sample exists to prove a vial is the real thing.

Updated 03 May 2026Read 4 minBacked by 60 studies

The quick version

What it is: A weekly shot that copies GLP-1 and pushes glucagon
Is it FDA-approved?: No. Still in late testing (Phase 3)
How strong is the proof?: Promising Phase 2 data, but no approval and no real product to buy
How you take it: A shot under the skin, once a week
Typical result: About 18.7% body weight lost at 46 weeks (Phase 2)
Biggest catch: You cannot confirm research vials are even the real drug

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

Survodutide is a weekly shot being tested for weight loss. It is made by a drug company called Boehringer Ingelheim.

It hits two targets. One is , the "I am full" signal also used by tirzepatide. The other is glucagon, which can push your body to burn more energy.

It is not . It is still in late-stage human testing, in trials called SYNCHRONIZE. Approval is not expected until 2027 or later.

Because it is so new, there is no official reference sample. That makes it very hard to confirm a research vial is really survodutide.

What people use it for.

The main goal is weight loss.

There is also a separate program for a liver disease called MASH (a serious form of fatty liver). The liver data is its own story and comes from a different trial.

It is not a recovery or anti-aging .

Does it actually work?

The early human data looks good, but it is still early.

In a Phase 2 obesity trial of 387 people, the top dose led to about 18.7% body weight loss at 46 weeks. In a Phase 2 liver trial, the top dose cleared the liver disease in about 83% of patients.

Two honest points. First, that 18.7% is in the same range as tirzepatide's Phase 3 (22.5%), not beyond it. It is not a clear upgrade. Second, there is no approved product yet, so you cannot buy a verified version.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

“Survodutide is the next big thing, better than Ozempic and tirzepatide.”

overblown

In its Phase 2 obesity trial the top dose took off about 18.7% of body weight. That lands in the same range as tirzepatide's 22.5%, not beyond it. It is not the clear upgrade the hype makes it out to be.

“The glucagon part means it burns more fat than a normal GLP-1.”

half true

Glucagon can push your body to burn more energy, which is the second target here. But the overall weight loss did not pass tirzepatide, and that same glucagon signal raises your heart rate.

“You can buy real survodutide from research vendors right now.”

It is not approved, expected 2027 at the earliest, and it is so new there is no official reference sample. Even a clean-looking cannot prove the powder is really survodutide, so you could be injecting anything.

“It is the one to get for fatty liver disease.”

unproven

A Phase 2 liver trial cleared the disease in about 83% of patients, which is a real signal. But that is a separate, still-running program, and the only versions on sale are unverifiable research vials. This is a job for a liver doctor and a trial, not a gray-market vial.

How you take it.

In the trials it is a shot under the skin, once a week. Like other drugs in this family, you start low and go up slowly. That is called .

The glucagon part raises your heart rate, much like retatrutide does.

Since it is not approved, there is no official dosing for everyday use. Anyone using a research version is guessing at the trial doses.

What to watch out for.

The common stuff

Like other drugs, expect stomach issues: nausea, vomiting, diarrhea, or constipation. These are usually worst right after a dose increase.

The serious stuff

It raises your heart rate. Do not use it if you have a heart rhythm problem, uncontrolled high blood pressure, or serious heart disease.
Avoid it if you or close family had a rare thyroid cancer called medullary thyroid carcinoma.
Research vials cannot be confirmed as the real drug. You might be injecting something else.

This is an unapproved drug. Talk to a real doctor. We are not your doctor.

Where people get it.

From safest to riskiest. None are great, because it is not approved.

Brand. Not available. The trials are still running.
. A few pharmacies sell it for $400-$800 a month, but they are on shaky legal ground for a drug that is not approved.
Research-only (). Sold "for research only," about $150-$400 a month. Highest risk. There is no reference sample, so identity is basically unconfirmable.
. Overseas raw, around $65 a month. Same identity problem, even worse.

The core trap here: with no official sample to compare against, even a clean-looking does not prove the vial holds survodutide.

Our honest take.

The early numbers are the real thing. In its Phase 2 obesity trial the top dose took off about 18.7% of body weight, which is a 210-pound person dropping close to 40 pounds, down to around 171. That is genuine -plus-glucagon weight loss.

Here is the catch you would actually run into. It is not approved, so the only versions on sale are research vials, and because the drug is so new there is no official reference sample to check them against. Even a clean-looking cannot prove the powder is really survodutide, so you could be paying for, and injecting, anything.

And the upside is not even a leap. That 18.7% lands in the same range as tirzepatide's Phase 3 (about 22.5%, that same 210-pound person dropping closer to 163), and tirzepatide is approved and on shelves. So the who-for is narrow: really just biopsy-confirmed MASH with a liver doctor who can get you into the trial. For plain weight loss, the verifiable version already exists.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

Learn about these too.

Retatrutide

Triple agonist · phase 3

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.